Renal Impaired Studies

  1. An open label, single-dose study of the effects of XXX 100 mg on the pharmacokinetic profile, safety and tolerability in patients with compromised renal function.
  2. Pharmacokinetics of XXX in patients with renal impairment.
  3. Comparison of the steady state pharmacokinetics of XXX,XXX and XXX in patients with chronic renal insufficiency.
  4. The pharmacokinetics of transnasal XXX in normal and renally impaired female subjects.
  5. Pharmacokinetics of oral and intramuscular XXX Tromethamine in geriatric and renally impaired subjects.
  6. Pharmacokinetics of oral XXX HCL in patients with renal dysfunction.
  7. Pharmacokinetics of intravenous XXX HCL in patients with renal dysfunction.
  8. XXX- Diuretic interaction and renal function.
  9. Effects of high doses of XXX tablets on the renal function of healthy young and elderly subjects.
  10. Multiple dose pharmacokinetics of XXX (10 mg, OD) in subjects with varying degrees of renal function.
  11. The pharmacokinetics of XXX (XX) in subjects with normal and impaired renal function.
  12. Single Dose Pharmacokinetic Study of Oral XXX in Patients with Mild, Moderate and Severe Renal Impairment.
  13. Pharmacokinetics and Protein Binding of Total (S plus R),(-)S and (+)R XXX in Renally Impaired and Healthy Volunteers.
  14. Single dose Pharmacokinetic and Safety Study of 1.4 mg Sub-cutaneous XXX in Patients with Mild, Moderate and Severe Renal Impairment.
  15. An Open-Phase I Study of the Pharmacokinetics and Tolerability of RP59500 (XXX/XXX) Administered as Repeated 7.5 mg/kg IV Doses to Patients Volunteers with Moderate or Severe Chronic Renal Failure.
  16. Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Efficacy, Safety, and Pharmacokinetic Study ofXXX in Hospitalized Patients with Hyponatremia Secondary to Liver Disease.
  17. Safety and Pharmacokinetic Profile of XXX in Male Subjects with Normal or Impaired Renal Function.
  18. A Supplemental Study to Validate the Sandwich Enzyme Linked Immunoassay (ELISA) Used to Analize XXX Serum Concentrations in End-Stage Renal Disease Patients on Hemodialysis.
  19. A Randomized, Controlled Study of the Efficacy and Safety of XXX in the Therapy of Diabetic Nephropathy.
  20. A Pharmacokinetic/pharmacodynamic Ascending Dose Study to Evaluate the Safety of a Single Dose of XXX in End-Stage Renal Disease Patients Undergoing Hemodialysis.
  21. Evaluation of the Safety and Pharmacokinetics of XXX Following Administration of Multiple Doses to Subjects with Severe Renal Impairment.
  22. A single dose pharmacokinetic study of XXX in healthy subjects and subjects with mild to severe impaired renal function.
  23. A study of the potential effect of age and renal function on the pharmacokinetics of a single oral dose of XXX XXX in Postmenopausal women.
  24. A single dose open label, parallel-group study to evaluate the pharmacokinetics of XXX in subjects with impaired renal function in comparison with age, sex, and weight matched healthy controls.
  25. Comparative effects on dynamic renal potassium handling of XXX versus ibuprofen.
  26. An open-label, non-randomized, parallel group study of XXX pharmacokinetics in subjects with normal renal function and subjects with mild and moderate renal impairment receiving 36 mg XXX twice daily and in subjects with severe renal impairment receiving 24 and 36 mg XXX once daily.
  27. A phase 1 single and multiple dose study to determine the safety, pharmacokinetics and pharmacodynamics of XXX capsule in subjects with moderate and severe renal impairment.
  28. Single dose, open-label, parallel group study to determine the pharmacokinetics of XXX in subjects with renal insufficiency compared with age, sex, height and weight matched healthy volunteers.
  29. A double-blind, randomized, placebo-controlled, two treatments, two-periods crossover study to evaluate the safety, blood pressure, and pharmacokinetics when the combination hormone therapy 3 mg XXX/1 mg XXXX is co-administered with 25 mg XXX to postmenopausal women with essential hypertension over a treatment period of 4 weeks.
  30. A randomized, double-blind, parallel group study to evaluate the renal effects of multiple doses of XXX in comparison with placebo in subjects with mild and moderate degrees of renal impairment.
  31. An open-label, randomized, multiple-dose study to evaluate XXX in steady-state pharmacokinetics and safety in subjects with varying degrees of renal function.